Read by QxMD icon Read


shared collection
34 papers 0 to 25 followers My list of recent lymphoma publications
Chadi Nabhan, Sonali M Smith, Adam S Cifu
No abstract text is available yet for this article.
May 17, 2016: JAMA: the Journal of the American Medical Association
Anas Younes, Jesus G Berdeja, Manish R Patel, Ian Flinn, John F Gerecitano, Sattva S Neelapu, Kevin R Kelly, Amanda R Copeland, Amy Akins, Myles S Clancy, Lucy Gong, Jing Wang, Anna Ma, Jaye L Viner, Yasuhiro Oki
BACKGROUND: Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited. CUDC-907 is an oral, first-in-class, small molecule that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematological malignancies. We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma...
May 2016: Lancet Oncology
E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, R Bouadballah, J Radford, M Bargetzi, V Ribrag, U Dührsen, D Ma, J Briere, C Thieblemont, E Bachy, C H Moskowitz, B Glass, C Gisselbrecht
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32...
September 19, 2016: Bone Marrow Transplantation
Connie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, Peter Lee, Lia Gore, Amanda Copeland, Rachel Sorensen, Peter Ordentlich, Scott Cruickshank, Lori Kunkel, Daniela Buglio, Francisco Hernandez-Ilizaliturri, Anas Younes
Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies. However, most patients do not achieve a complete response, therefore development of novel therapies is warranted to improve patient outcomes. In this phase II study, patients with relapsed or refractory Hodgkin lymphoma were treated with entinostat, an isoform selective histone deacetylase inhibitor. Forty-nine patients were enrolled: 33 patients on Schedule A (10 or 15 mg oral entinostat once every other week); 16 patients on Schedule B (15 mg oral entinostat once weekly in 3 of 4 weeks)...
August 2016: Haematologica
Pier Luigi Zinzani, Cinzia Pellegrini, Lisa Argnani, Alessandro Broccoli
No abstract text is available yet for this article.
September 2016: Haematologica
Harriet S Walter, Gilles A Salles, Martin J S Dyer
No abstract text is available yet for this article.
June 2, 2016: New England Journal of Medicine
Jae H Park, Mark B Geyer, Renier J Brentjens
Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B-cell malignancies. Although these CAR-modified T cells target the same antigen, the designs of CARs vary as well as several key aspects of the clinical trials in which these CARs have been studied. It is unclear whether these differences have any impact on clinical outcome and treatment-related toxicities. Herein, we review clinical results reflecting the investigational use of CD19-targeted CAR T-cell therapeutics in patients with B-cell hematologic malignancies, in light of differences in CAR design and production, and outline the limitations inherent in comparing outcomes between studies...
June 30, 2016: Blood
Jennifer N Brudno, James N Kochenderfer
Chimeric antigen receptor (CAR) T cells can produce durable remissions in hematologic malignancies that are not responsive to standard therapies. Yet the use of CAR T cells is limited by potentially severe toxicities. Early case reports of unexpected organ damage and deaths following CAR T-cell therapy first highlighted the possible dangers of this new treatment. CAR T cells can potentially damage normal tissues by specifically targeting a tumor-associated antigen that is also expressed on those tissues. Cytokine release syndrome (CRS), a systemic inflammatory response caused by cytokines released by infused CAR T cells can lead to widespread reversible organ dysfunction...
June 30, 2016: Blood
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F Seymour, Talha Munir, Soham D Puvvada, Clemens-Martin Wendtner, Andrew W Roberts, Wojciech Jurczak, Stephen P Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari Heitner Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G Wierda
BACKGROUND: Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy. Venetoclax is an oral small-molecule BCL2 inhibitor that induces chronic lymphocytic leukaemia cell apoptosis. In a previous first-in-human study of venetoclax, 77% of patients with relapsed or refractory chronic lymphocytic leukaemia achieved an overall response. Here we aimed to assess the activity and safety of venetoclax monotherapy in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia...
June 2016: Lancet Oncology
Gregory A Abel, Randy Albelda, Nandita Khera, Theresa Hahn, Diana Y Salas Coronado, Oreofe O Odejide, Kira Bona, Reginald Tucker-Seeley, Robert Soiffer
Although hematopoietic cell transplantation (HCT) is the only curative therapy for many advanced hematologic cancers, little is known about the financial hardship experienced by HCT patients nor the association of hardship with patient-reported outcomes. We mailed a 43-item survey to adult patients approximately 180 days after their first autologous or allogeneic HCT at 3 high-volume centers. We assessed decreases in household income; difficulty with HCT-related costs, such as need to relocate or travel; and 2 types of hardship: hardship_1 (reporting 1 or 2 of the following: dissatisfaction with present finances, difficulty meeting monthly bill payments, or not having enough money at the end of the month) and "hardship_2" (reporting all 3)...
August 2016: Biology of Blood and Marrow Transplantation
L Valls, C Badve, S Avril, K Herrmann, P Faulhaber, J O'Donnell, N Avril
The majority of aggressive lymphomas is characterized by an up regulated glycolytic activity, which enables the visualization by F-18 FDG-PET/CT. One-stop hybrid FDG-PET/CT combines the functional and morphologic information, outperforming both, CT and FDG-PET as separate imaging modalities. This has resulted in several recommendations using FDG-PET/CT for staging, restaging, monitoring during therapy, and assessment of treatment response as well as identification of malignant transformation. FDG-PET/CT may obviate the need for a bone marrow biopsy in patients with Hodgkin's lymphoma and diffuse large B cell lymphoma...
July 2016: Blood Reviews
Ginna G Laport, Juan Wu, Brent Logan, Veronika Bachanova, Chitra Hosing, Timothy Fenske, Walter Longo, Steven M Devine, Auayporn Nademanee, Iris Gersten, Mary Horowitz, Hillard M Lazarus, Marcie L Riches
Allogeneic (allo) hematopoietic cell transplantation (HCT) can induce long-term remissions in chemosensitive relapsed follicular lymphoma (FL). The Blood and Marrow Transplant Clinical Trials Network conducted a multicenter phase 2 trial to examine the efficacy of alloHCT using reduced-intensity conditioning with rituximab (RTX) in multiply relapsed, chemosensitive FL. The primary endpoint was 2-year progression-free survival (PFS). The conditioning regimen consisted of fludarabine, cyclophosphamide, and high-dose RTX (FCR), in which 3 of the 4 doses of RTX were administered at a dose of 1 gm/m(2)...
August 2016: Biology of Blood and Marrow Transplantation
Gero Knittel, Paul Liedgens, Darya Korovkina, Jens M Seeger, Yussor Al-Baldawi, Mona Al-Maarri, Christian Fritz, Katerina Vlantis, Svetlana Bezhanova, Andreas H Scheel, Olaf-Oliver Wolz, Maurice Reimann, Peter Möller, Cristina López, Matthias Schlesner, Philipp Lohneis, Alexander N R Weber, Lorenz Trümper, Louis M Staudt, Monika Ortmann, Manolis Pasparakis, Reiner Siebert, Clemens A Schmitt, Andreas R Klatt, F Thomas Wunderlich, Stephan C Schäfer, Thorsten Persigehl, Manuel Montesinos-Rongen, Margarete Odenthal, Reinhard Büttner, Lukas P Frenzel, Hamid Kashkar, H Christian Reinhardt
The adaptor protein MYD88 is critical for relaying activation of Toll-like receptor signaling to NF-κB activation. MYD88 mutations, particularly the p.L265P mutation, have been described in numerous distinct B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Twenty-nine percent of activated B-cell-type DLBCL (ABC-DLBCL), which is characterized by constitutive activation of the NF-κB pathway, carry the p.L265P mutation. In addition, ABC-DLBCL frequently displays focal copy number gains affecting BCL2 Here, we generated a novel mouse model in which Cre-mediated recombination, specifically in B cells, leads to the conditional expression of Myd88(p...
June 2, 2016: Blood
Zijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, Alexander Tzankov, Ling Li, Yi Xia, Xiao-Xiao Wang, Dehui Zou, Carlo Visco, Karen Dybkær, Jun Li, Li Zhang, Han Liang, Santiago Montes-Moreno, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L Richards, Eric D Hsi, William W L Choi, J Han van Krieken, Jooryung Huh, Maurilio Ponzoni, Andrés J M Ferreri, Ben M Parsons, Michael B Møller, Sa A Wang, Roberto N Miranda, Miguel A Piris, Jane N Winter, L Jeffrey Medeiros, Yong Li, Ken H Young
PURPOSE: MYC is a critical driver oncogene in many cancers, and its deregulation in the forms of translocation and overexpression has been implicated in lymphomagenesis and progression of diffuse large B-cell lymphoma (DLBCL). The MYC mutational profile and its roles in DLBCL are unknown. This study aims to determine the spectrum of MYC mutations in a large group of patients with DLBCL, and to evaluate the clinical significance of MYC mutations in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy...
July 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Daniel J Hodson, Arthur L Shaffer, Wenming Xiao, George W Wright, Roland Schmitz, James D Phelan, Yandan Yang, Daniel E Webster, Lixin Rui, Holger Kohlhammer, Masao Nakagawa, Thomas A Waldmann, Louis M Staudt
The requirement for the B-cell transcription factor OCT2 (octamer-binding protein 2, encoded by Pou2f2) in germinal center B cells has proved controversial. Here, we report that germinal center B cells are formed normally after depletion of OCT2 in a conditional knockout mouse, but their proliferation is reduced and in vivo differentiation to antibody-secreting plasma cells is blocked. This finding led us to examine the role of OCT2 in germinal center-derived lymphomas. shRNA knockdown showed that almost all diffuse large B-cell lymphoma (DLBCL) cell lines are addicted to the expression of OCT2 and its coactivator OCA-B...
April 5, 2016: Proceedings of the National Academy of Sciences of the United States of America
Stephen M Ansell
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 9,050 new patients annually and representing approximately 11.2% of all lymphomas in the United States. DIAGNOSIS: HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups under the designation of classical HL...
June 2016: American Journal of Hematology
Patrice Carde, Matthias Karrasch, Catherine Fortpied, Pauline Brice, Hussein Khaled, Olivier Casasnovas, Denis Caillot, Isabelle Gaillard, Serge Bologna, Christophe Ferme, Pieternella Johanna Lugtenburg, Frank Morschhauser, Igor Aurer, Bertrand Coiffier, Ralph Meyer, Matthew Seftel, Max Wolf, Bengt Glimelius, Anna Sureda, Nicolas Mounier
PURPOSE: To compare patients with high-risk stage III to IV Hodgkin lymphoma (HL) in the phase III European Organisation for Research and Treatment of Cancer 20012 Intergroup trial (Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma) who were randomly assigned to either doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)...
June 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Danny N Khalil, Eric L Smith, Renier J Brentjens, Jedd D Wolchok
No abstract text is available yet for this article.
June 2016: Nature Reviews. Clinical Oncology
George P Souroullas, William R Jeck, Joel S Parker, Jeremy M Simon, Jie-Yu Liu, Joshiawa Paulk, Jessie Xiong, Kelly S Clark, Yuri Fedoriw, Jun Qi, Christin E Burd, James E Bradner, Norman E Sharpless
B cell lymphoma and melanoma harbor recurrent mutations in the gene encoding the EZH2 histone methyltransferase (EZH2), but the carcinogenic role of these mutations is unclear. Here we describe a mouse model in which the most common somatic Ezh2 gain-of-function mutation (EZH2(Y646F) in human; Ezh2(Y641F) in mouse) is conditionally expressed. Expression of Ezh2(Y641F) in mouse B cells or melanocytes caused high-penetrance lymphoma or melanoma, respectively. Overexpression of the anti-apoptotic protein Bcl2, but not the oncoprotein Myc, or loss of the tumor suppressor protein p53 (encoded by Trp53 in mice) further accelerated lymphoma progression...
June 2016: Nature Medicine
Hui Jing, Jing Hu, Bin He, Yashira L Negrón Abril, Jack Stupinski, Keren Weiser, Marisa Carbonaro, Ying-Ling Chiang, Teresa Southard, Paraskevi Giannakakou, Robert S Weiss, Hening Lin
No abstract text is available yet for this article.
April 11, 2016: Cancer Cell
2016-05-04 23:55:10
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"